ストックスクリーナーアプリを入手
4.41
6.96%
-0.33
アフターアワーズ：
4.41
前日終値:
$4.74
開ける：
$4.68
24時間の取引高:
87,052
Relative Volume:
0.99
時価総額：
$114.09M
収益：
-
当期純損益:
$-35.46M
株価収益率:
-10.46
EPS:
-0.4218
ネットキャッシュフロー:
$-34.00M
1週間 パフォーマンス:
+29.71%
1か月 パフォーマンス:
+7.56%
6か月 パフォーマンス:
-68.79%
1年 パフォーマンス:
-71.96%
1日の値動き範囲:
$4.3862
$4.76
1週間の範囲:
$3.35
$4.76
52週間の値動き範囲:
$3.35
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
名前
Contineum Therapeutics Inc
セクター
電話
(858) 333-5280
住所
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
CTNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
4.41 | 87.96M | 0 | -35.46M | -34.00M | -0.4218 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-22 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-30 | 開始されました | Stifel | Buy |
Contineum Therapeutics Inc (CTNM) 最新ニュース
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Deutsche Bank AG Purchases New Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Northern Trust Corp Increases Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics ATM - Leerink Partners
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook By Investing.com - Investing.com South Africa
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook - Investing.com
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $20.00 at Morgan Stanley - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Earns Outperform Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference - BioSpace
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum Therapeutics May 2025 slides: Multiple shots on goal with 2H25 catalysts ahead - Investing.com India
Barclays PLC Buys 7,978 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Wells Fargo & Company MN Raises Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (CTNM) Expected to Announce Earnings on Thursday - Defense World
(CTNM) Investment Analysis - news.stocktradersdaily.com
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
JPMorgan Chase & Co. Has $416,000 Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., As Chief Medical Officer - citybiz
Geode Capital Management LLC Purchases 59,732 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - BioSpace
Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development - marketscreener.com
Form 8-KCurrent report - ADVFN
Critical Contrast: Contineum Therapeutics (CTNM) and Its Rivals - Defense World
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate - Yahoo Finance
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
(CTNM) On The My Stocks Page - news.stocktradersdaily.com
Contineum Therapeutics (CTNM) vs. Its Competitors Head-To-Head Survey - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from Analysts - Defense World
Contineum Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Contineum Therapeutics Rings the Closing Bell - Nasdaq
How the (CTNM) price action is used to our Advantage - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Charles Schwab Investment Management Inc. Buys 12,035 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - The AM Reporter
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Jones Trading Initiates Coverage of Contineum Therapeutics (CTNM) with Buy Recommendation - Nasdaq
JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target -March 13, 2025 at 08:48 am EDT - Marketscreener.com
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24% - Yahoo Finance
Contineum Therapeutics Inc (CTNM) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):